{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,4]],"date-time":"2026-08-04T08:43:27Z","timestamp":1785833007577,"version":"3.56.0"},"reference-count":72,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,12,11]],"date-time":"2024-12-11T00:00:00Z","timestamp":1733875200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100021528","name":"Advancing a Healthier Wisconsin Endowment","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100021528","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000065","name":"National Institute of Neurological Disorders and Stroke","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000065","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["cell.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Molecular Therapy"],"published-print":{"date-parts":[[2025,2]]},"DOI":"10.1016\/j.ymthe.2024.12.016","type":"journal-article","created":{"date-parts":[[2024,12,12]],"date-time":"2024-12-12T19:22:31Z","timestamp":1734031351000},"page":"734-751","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"title":["IL-1ra and CCL5, but not IL-10, are promising targets for treating SMA astrocyte-driven pathology"],"prefix":"10.1016","volume":"33","author":[{"given":"Reilly L.","family":"Allison","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cecelia C.","family":"Mangione","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mya","family":"Suneja","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jessica","family":"Gawrys","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brendan M.","family":"Melvin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Natalya","family":"Belous","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Megan","family":"LaCroix","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew","family":"Harmelink","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Barrington G.","family":"Burnett","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9676-8548","authenticated-orcid":false,"given":"Allison D.","family":"Ebert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ymthe.2024.12.016_bib1","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1016\/j.nurt.2008.08.007","article-title":"Spinal muscular atrophy","volume":"5","author":"Oskoui","year":"2008","journal-title":"Neurotherapeutics"},{"key":"10.1016\/j.ymthe.2024.12.016_bib2","doi-asserted-by":"crossref","first-page":"3877","DOI":"10.1007\/s00018-018-2849-1","article-title":"The role of survival motor neuron protein (SMN) in protein homeostasis","volume":"75","author":"Chaytow","year":"2018","journal-title":"Cell. Mol. Life Sci."},{"key":"10.1016\/j.ymthe.2024.12.016_bib3","doi-asserted-by":"crossref","first-page":"3818","DOI":"10.1523\/JNEUROSCI.5775-11.2012","article-title":"Motor neuron rescue in spinal muscular atrophy mice demonstrates that sensory-motor defects are a consequence, not a cause, of motor neuron dysfunction","volume":"32","author":"Gogliotti","year":"2012","journal-title":"J.\u00a0Neurosci."},{"key":"10.1016\/j.ymthe.2024.12.016_bib4","doi-asserted-by":"crossref","first-page":"8703","DOI":"10.1523\/JNEUROSCI.0204-12.2012","article-title":"Survival motor neuron protein in motor neurons determines synaptic integrity in spinal muscular atrophy","volume":"32","author":"Martinez","year":"2012","journal-title":"J.\u00a0Neurosci."},{"key":"10.1016\/j.ymthe.2024.12.016_bib5","doi-asserted-by":"crossref","first-page":"12005","DOI":"10.1523\/JNEUROSCI.2208-10.2010","article-title":"Reduced survival of motor neuron (SMN) protein in motor neuronal progenitors functions cell autonomously to cause spinal muscular atrophy in model mice expressing the human centromeric (SMN2) gene","volume":"30","author":"Park","year":"2010","journal-title":"J.\u00a0Neurosci."},{"key":"10.1016\/j.ymthe.2024.12.016_bib6","article-title":"Limited Phenotypic Effects of Selectively Augmenting the SMN Protein in the Neurons of a Mouse Model of Severe Spinal Muscular Atrophy","volume":"7","author":"Lee","year":"2012","journal-title":"PLoS One"},{"key":"10.1016\/j.ymthe.2024.12.016_bib7","doi-asserted-by":"crossref","first-page":"1418","DOI":"10.1002\/glia.22522","article-title":"Spinal muscular atrophy astrocytes exhibit abnormal calcium regulation and reduced growth factor production","volume":"61","author":"McGivern","year":"2013","journal-title":"Glia"},{"key":"10.1016\/j.ymthe.2024.12.016_bib8","doi-asserted-by":"crossref","first-page":"3409","DOI":"10.1093\/hmg\/ddx230","article-title":"Astrocyte-produced miR-146a as a mediator of motor neuron loss in spinal muscular atrophy","volume":"26","author":"Sison","year":"2017","journal-title":"Hum. Mol. Genet."},{"key":"10.1016\/j.ymthe.2024.12.016_bib9","doi-asserted-by":"crossref","first-page":"4094","DOI":"10.1093\/hmg\/ddv148","article-title":"Astrocytes influence the severity of spinal muscular atrophy","volume":"24","author":"Rindt","year":"2015","journal-title":"Hum. Mol. Genet."},{"key":"10.1016\/j.ymthe.2024.12.016_bib10","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1002\/glia.24153","article-title":"Viral mediated knockdown of GATA6 in SMA iPSC-derived astrocytes prevents motor neuron loss and microglial activation","volume":"70","author":"Allison","year":"2022","journal-title":"Glia"},{"key":"10.1016\/j.ymthe.2024.12.016_bib11","doi-asserted-by":"crossref","first-page":"3087","DOI":"10.1016\/j.celrep.2019.11.013","article-title":"The Classical Complement Pathway Mediates Microglia-Dependent Remodeling of Spinal Motor Circuits during Development and in SMA","volume":"29","author":"Vukojicic","year":"2019","journal-title":"Cell Rep."},{"key":"10.1016\/j.ymthe.2024.12.016_bib12","article-title":"New and Developing Therapies in Spinal Muscular Atrophy: From Genotype to Phenotype to Treatment and Where Do We Stand?","volume":"21","author":"Chen","year":"2020","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.ymthe.2024.12.016_bib13","doi-asserted-by":"crossref","first-page":"890","DOI":"10.1212\/WNL.0000000000002445","article-title":"Results from a phase 1 study of nusinersen (ISIS-SMN(Rx)) in children with spinal muscular atrophy","volume":"86","author":"Chiriboga","year":"2016","journal-title":"Neurology"},{"key":"10.1016\/j.ymthe.2024.12.016_bib14","doi-asserted-by":"crossref","first-page":"3017","DOI":"10.1016\/S0140-6736(16)31408-8","article-title":"Treatment of infantile-onset spinal muscular atrophy with nusinersen: a phase 2, open-label, dose-escalation study","volume":"388","author":"Finkel","year":"2016","journal-title":"Lancet"},{"key":"10.1016\/j.ymthe.2024.12.016_bib15","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1001\/jamapediatrics.2017.4409","article-title":"Ethical Challenges Confronted When Providing Nusinersen Treatment for Spinal Muscular Atrophy","volume":"172","author":"Burgart","year":"2018","journal-title":"JAMA Pediatr."},{"key":"10.1016\/j.ymthe.2024.12.016_bib16","first-page":"194","article-title":"Nusinersen: A Novel Antisense Oligonucleotide for the Treatment of Spinal Muscular Atrophy","volume":"24","author":"Neil","year":"2019","journal-title":"J.\u00a0Pediatr. Pharmacol. Ther."},{"key":"10.1016\/j.ymthe.2024.12.016_bib17","doi-asserted-by":"crossref","first-page":"3219","DOI":"10.1172\/JCI121658","article-title":"Two breakthrough gene-targeted treatments for spinal muscular atrophy: challenges remain","volume":"128","author":"Sumner","year":"2018","journal-title":"J.\u00a0Clin. Invest."},{"key":"10.1016\/j.ymthe.2024.12.016_bib18","article-title":"Nusinersen treatment of spinal muscular atrophy - a systematic review","volume":"67","author":"Albrechtsen","year":"2020","journal-title":"Dan. Med. J."},{"key":"10.1016\/j.ymthe.2024.12.016_bib19","doi-asserted-by":"crossref","first-page":"842","DOI":"10.1016\/j.nmd.2019.09.007","article-title":"Nusinersen initiated in infants during the presymptomatic stage of spinal muscular atrophy: Interim efficacy and safety results from the Phase 2 NURTURE study","volume":"29","author":"De Vivo","year":"2019","journal-title":"Neuromuscul. Disord."},{"key":"10.1016\/j.ymthe.2024.12.016_bib20","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1038\/nbt.1610","article-title":"Rescue of the spinal muscular atrophy phenotype in a mouse model by early postnatal delivery of SMN","volume":"28","author":"Foust","year":"2010","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.ymthe.2024.12.016_bib21","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1089\/hum.2011.166","article-title":"Decreasing disease severity in symptomatic, Smn(-\/-);SMN2(+\/+), spinal muscular atrophy mice following scAAV9-SMN delivery","volume":"23","author":"Glascock","year":"2012","journal-title":"Hum. Gene Ther."},{"key":"10.1016\/j.ymthe.2024.12.016_bib22","doi-asserted-by":"crossref","first-page":"1253","DOI":"10.1172\/JCI41615","article-title":"CNS-targeted gene therapy improves survival and motor function in a mouse model of spinal muscular atrophy","volume":"120","author":"Passini","year":"2010","journal-title":"J.\u00a0Clin. Invest."},{"key":"10.1016\/j.ymthe.2024.12.016_bib23","doi-asserted-by":"crossref","first-page":"4559","DOI":"10.1093\/hmg\/ddu169","article-title":"Defining the therapeutic window in a severe animal model of spinal muscular atrophy","volume":"23","author":"Robbins","year":"2014","journal-title":"Hum. Mol. Genet."},{"key":"10.1016\/j.ymthe.2024.12.016_bib24","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.3001777","article-title":"Antisense oligonucleotides delivered to the mouse CNS ameliorate symptoms of severe spinal muscular atrophy","volume":"3","author":"Passini","year":"2011","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.ymthe.2024.12.016_bib25","doi-asserted-by":"crossref","first-page":"1625","DOI":"10.1093\/hmg\/ddr600","article-title":"A single administration of morpholino antisense oligomer rescues spinal muscular atrophy in mouse","volume":"21","author":"Porensky","year":"2012","journal-title":"Hum. Mol. Genet."},{"key":"10.1016\/j.ymthe.2024.12.016_bib26","doi-asserted-by":"crossref","first-page":"eabb6871","DOI":"10.1126\/scitranslmed.abb6871","article-title":"Impaired prenatal motor axon development necessitates early therapeutic intervention in severe SMA","volume":"13","author":"Kong","year":"2021","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.ymthe.2024.12.016_bib27","doi-asserted-by":"crossref","first-page":"458","DOI":"10.3389\/fncel.2018.00458","article-title":"The Interleukin-10 Family of Cytokines and Their Role in the CNS","volume":"12","author":"Burmeister","year":"2018","journal-title":"Front. Cell. Neurosci."},{"key":"10.1016\/j.ymthe.2024.12.016_bib28","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1007\/s12079-015-0302-x","article-title":"A network map of Interleukin-10 signaling pathway","volume":"10","author":"Verma","year":"2016","journal-title":"J.\u00a0Cell Commun. Signal."},{"key":"10.1016\/j.ymthe.2024.12.016_bib29","doi-asserted-by":"crossref","first-page":"16513","DOI":"10.1074\/jbc.274.23.16513","article-title":"Interleukin-10 receptor signaling through the JAK-STAT pathway. Requirement for two distinct receptor-derived signals for anti-inflammatory action","volume":"274","author":"Riley","year":"1999","journal-title":"J.\u00a0Biol. Chem."},{"key":"10.1016\/j.ymthe.2024.12.016_bib30","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1006\/bbrc.2000.3023","article-title":"Stimulus-specific inhibition of IL-5 by cAMP-elevating agents and IL-10 reveals differential mechanisms of action","volume":"273","author":"Staples","year":"2000","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"10.1016\/j.ymthe.2024.12.016_bib31","doi-asserted-by":"crossref","DOI":"10.7554\/eLife.68054","article-title":"SMA-miRs (miR-181a-5p, -324-5p, and -451a) are overexpressed in spinal muscular atrophy skeletal muscle and serum samples","volume":"10","author":"Abiusi","year":"2021","journal-title":"Elife"},{"key":"10.1016\/j.ymthe.2024.12.016_bib32","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1186\/s12974-016-0763-8","article-title":"Balancing the immune response in the brain: IL-10 and its regulation","volume":"13","author":"Lobo-Silva","year":"2016","journal-title":"J.\u00a0Neuroinflammation"},{"key":"10.1016\/j.ymthe.2024.12.016_bib33","doi-asserted-by":"crossref","first-page":"1617","DOI":"10.1111\/j.1471-4159.2009.06263.x","article-title":"Interleukin-10 provides direct trophic support to neurons","volume":"110","author":"Zhou","year":"2009","journal-title":"J.\u00a0Neurochem."},{"key":"10.1016\/j.ymthe.2024.12.016_bib34","doi-asserted-by":"crossref","DOI":"10.1101\/cshperspect.a028548","article-title":"Targeting IL-10 Family Cytokines for the Treatment of Human Diseases","volume":"11","author":"Wang","year":"2019","journal-title":"Cold Spring Harb. Perspect. Biol."},{"key":"10.1016\/j.ymthe.2024.12.016_bib35","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1016\/0955-2235(90)90018-F","article-title":"Interleukin-1 receptor antagonist: discovery, structure and properties","volume":"2","author":"Arend","year":"1990","journal-title":"Prog. Growth Factor Res."},{"key":"10.1016\/j.ymthe.2024.12.016_bib36","doi-asserted-by":"crossref","first-page":"647","DOI":"10.3233\/ADR-210026","article-title":"Upregulation of IL-1 Receptor Antagonist by Aspirin in Glial Cells via Peroxisome Proliferator-Activated Receptor-Alpha","volume":"5","author":"Chakrabarti","year":"2021","journal-title":"J.\u00a0Alzheimers Dis. Rep."},{"key":"10.1016\/j.ymthe.2024.12.016_bib37","doi-asserted-by":"crossref","first-page":"845","DOI":"10.1093\/hmg\/ddi078","article-title":"SMNDelta7, the major product of the centromeric survival motor neuron (SMN2) gene, extends survival in mice with spinal muscular atrophy and associates with full-length SMN","volume":"14","author":"Le","year":"2005","journal-title":"Hum. Mol. Genet."},{"key":"10.1016\/j.ymthe.2024.12.016_bib38","doi-asserted-by":"crossref","first-page":"1311","DOI":"10.1002\/glia.24340","article-title":"Diminished motor neuron activity driven by abnormal astrocytic EAAT1 glutamate transporter activity in spinal muscular atrophy is not fully restored after lentiviral SMN delivery","volume":"71","author":"Welby","year":"2023","journal-title":"Glia"},{"key":"10.1016\/j.ymthe.2024.12.016_bib39","doi-asserted-by":"crossref","DOI":"10.3390\/genes13020241","article-title":"Microglia Influence Neurofilament Deposition in ALS iPSC-Derived Motor Neurons","volume":"13","author":"Allison","year":"2022","journal-title":"Genes (Basel)"},{"key":"10.1016\/j.ymthe.2024.12.016_bib40","doi-asserted-by":"crossref","first-page":"1079","DOI":"10.3389\/fimmu.2017.01079","article-title":"CCL5-Glutamate Cross-Talk in Astrocyte-Neuron Communication in Multiple Sclerosis","volume":"8","author":"Pittaluga","year":"2017","journal-title":"Front. Immunol."},{"key":"10.1016\/j.ymthe.2024.12.016_bib41","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0163954","article-title":"Altered mRNA Splicing in SMN-Depleted Motor Neuron-Like Cells","volume":"11","author":"Custer","year":"2016","journal-title":"PLoS One"},{"key":"10.1016\/j.ymthe.2024.12.016_bib42","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1002\/emmm.201202303","article-title":"Spliceosome integrity is defective in the motor neuron diseases ALS and SMA","volume":"5","author":"Tsuiji","year":"2013","journal-title":"EMBO Mol. Med."},{"key":"10.1016\/j.ymthe.2024.12.016_bib43","article-title":"Spinal muscular atrophy patient-derived motor neurons exhibit hyperexcitability","volume":"5","author":"Liu","year":"2015","journal-title":"Sci. Rep."},{"key":"10.1016\/j.ymthe.2024.12.016_bib44","doi-asserted-by":"crossref","first-page":"1297","DOI":"10.1152\/jn.00652.2018","article-title":"Hyperexcitability precedes motoneuron loss in the","volume":"122","author":"Quinlan","year":"2019","journal-title":"J.\u00a0Neurophysiol."},{"key":"10.1016\/j.ymthe.2024.12.016_bib45","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1146\/annurev.immunol.19.1.683","article-title":"Interleukin-10 and the interleukin-10 receptor","volume":"19","author":"Moore","year":"2001","journal-title":"Annu. Rev. Immunol."},{"key":"10.1016\/j.ymthe.2024.12.016_bib46","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1016\/j.neurobiolaging.2016.04.014","article-title":"Insensitivity of astrocytes to interleukin 10 signaling following peripheral immune challenge results in prolonged microglial activation in the aged brain","volume":"44","author":"Norden","year":"2016","journal-title":"Neurobiol. Aging"},{"key":"10.1016\/j.ymthe.2024.12.016_bib47","doi-asserted-by":"crossref","first-page":"4021","DOI":"10.1161\/STROKEAHA.120.033285","article-title":"CCR5 Activation Promotes NLRP1-Dependent Neuronal Pyroptosis via CCR5\/PKA\/CREB Pathway After Intracerebral Hemorrhage","volume":"52","author":"Yan","year":"2021","journal-title":"Stroke"},{"key":"10.1016\/j.ymthe.2024.12.016_bib48","doi-asserted-by":"crossref","DOI":"10.7554\/eLife.20985","article-title":"CCR5 is a suppressor for cortical plasticity and hippocampal learning and memory","volume":"5","author":"Zhou","year":"2016","journal-title":"Elife"},{"key":"10.1016\/j.ymthe.2024.12.016_bib49","doi-asserted-by":"crossref","DOI":"10.3390\/ijms21124291","article-title":"Multiple Roles of Transforming Growth Factor Beta in Amyotrophic Lateral Sclerosis","volume":"21","author":"Galbiati","year":"2020","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.ymthe.2024.12.016_bib50","doi-asserted-by":"crossref","first-page":"5702","DOI":"10.1523\/JNEUROSCI.0388-10.2010","article-title":"Disrupted transforming growth factor-beta signaling in spinal and bulbar muscular atrophy","volume":"30","author":"Katsuno","year":"2010","journal-title":"J.\u00a0Neurosci."},{"key":"10.1016\/j.ymthe.2024.12.016_bib51","first-page":"39","article-title":"Advances in Newborn Screening and Presymptomatic Diagnosis of Spinal Muscular Atrophy","volume":"10","author":"J\u0119drzejowska","year":"2020","journal-title":"Degener. Neurol. Neuromuscul. Dis."},{"key":"10.1016\/j.ymthe.2024.12.016_bib52","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1093\/hmg\/ddv489","article-title":"SMN deficiency does not induce oxidative stress in SMA iPSC-derived astrocytes or motor neurons","volume":"25","author":"Patitucci","year":"2016","journal-title":"Hum. Mol. Genet."},{"key":"10.1016\/j.ymthe.2024.12.016_bib53","doi-asserted-by":"crossref","first-page":"3415","DOI":"10.1093\/hmg\/ddt191","article-title":"Celecoxib increases SMN and survival in a severe spinal muscular atrophy mouse model via p38 pathway activation","volume":"22","author":"Farooq","year":"2013","journal-title":"Hum. Mol. Genet."},{"key":"10.1016\/j.ymthe.2024.12.016_bib54","doi-asserted-by":"crossref","first-page":"3021","DOI":"10.1096\/fj.201802554RRR","article-title":"Drosophila SMN2\u00a0minigene reporter model identifies moxifloxacin as a candidate therapy for SMA","volume":"34","author":"Konieczny","year":"2020","journal-title":"FASEB J."},{"key":"10.1016\/j.ymthe.2024.12.016_bib55","unstructured":"McMillan H. Effect of Low-Dose Celecoxib on SMN2 in Patients With Spinal Muscular Atrophy (SMA). ClinicalTrials.gov2020."},{"key":"10.1016\/j.ymthe.2024.12.016_bib56","doi-asserted-by":"crossref","first-page":"530","DOI":"10.1093\/hmg\/ddad209","article-title":"ALS iPSC-derived microglia and motor neurons respond to astrocyte-targeted IL-10 and CCL2 modulation","volume":"33","author":"Allison","year":"2024","journal-title":"Hum. Mol. Genet."},{"key":"10.1016\/j.ymthe.2024.12.016_bib57","doi-asserted-by":"crossref","first-page":"913","DOI":"10.1002\/glia.24147","article-title":"Astrocyte immunosenescence and deficits in interleukin 10 signaling in the aged brain disrupt the regulation of microglia following innate immune activation","volume":"70","author":"O'Neil","year":"2022","journal-title":"Glia"},{"key":"10.1016\/j.ymthe.2024.12.016_bib58","doi-asserted-by":"crossref","DOI":"10.1016\/j.fct.2019.110719","article-title":"Activation of pCREB\/Nrf-2 signaling mediates re-positioning of liraglutide as hepato-protective for methotrexate -induced liver injury (MILI)","volume":"132","author":"Abdelaziz","year":"2019","journal-title":"Food Chem. Toxicol."},{"key":"10.1016\/j.ymthe.2024.12.016_bib59","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1111\/imr.12621","article-title":"Overview of the IL-1 family in innate inflammation and acquired immunity","volume":"281","author":"Dinarello","year":"2018","journal-title":"Immunol. Rev."},{"key":"10.1016\/j.ymthe.2024.12.016_bib60","doi-asserted-by":"crossref","first-page":"1163","DOI":"10.1002\/art.40865","article-title":"Treatment to Target Using Recombinant Interleukin-1 Receptor Antagonist as First-Line Monotherapy in New-Onset Systemic Juvenile Idiopathic Arthritis: Results From a Five-Year Follow-Up Study","volume":"71","author":"Ter Haar","year":"2019","journal-title":"Arthritis Rheumatol."},{"key":"10.1016\/j.ymthe.2024.12.016_bib61","doi-asserted-by":"crossref","first-page":"1034","DOI":"10.1002\/art.38296","article-title":"Effectiveness of first-line treatment with recombinant interleukin-1 receptor antagonist in steroid-naive patients with new-onset systemic juvenile idiopathic arthritis: results of a prospective cohort study","volume":"66","author":"Vastert","year":"2014","journal-title":"Arthritis Rheumatol."},{"key":"10.1016\/j.ymthe.2024.12.016_bib62","doi-asserted-by":"crossref","first-page":"881","DOI":"10.1002\/glia.22647","article-title":"TGF\u03b2 produced by IL-10 redirected astrocytes attenuates microglial activation","volume":"62","author":"Norden","year":"2014","journal-title":"Glia"},{"key":"10.1016\/j.ymthe.2024.12.016_bib63","doi-asserted-by":"crossref","first-page":"8686","DOI":"10.1073\/pnas.0500419102","article-title":"The primary mechanism of the IL-10-regulated antiinflammatory response is to selectively inhibit transcription","volume":"102","author":"Murray","year":"2005","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.ymthe.2024.12.016_bib64","doi-asserted-by":"crossref","first-page":"1327","DOI":"10.1016\/S1097-2765(02)00541-5","article-title":"Both natural and designed micro RNAs can inhibit the expression of cognate mRNAs when expressed in human cells","volume":"9","author":"Zeng","year":"2002","journal-title":"Mol. Cell"},{"key":"10.1016\/j.ymthe.2024.12.016_bib65","doi-asserted-by":"crossref","first-page":"13212","DOI":"10.1073\/pnas.0506306102","article-title":"A lentiviral microRNA-based system for single-copy polymerase II-regulated RNA interference in mammalian cells","volume":"102","author":"Stegmeier","year":"2005","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.ymthe.2024.12.016_bib66","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1038\/s41419-019-1329-3","article-title":"Astrocytic miR-324-5p is essential for synaptic formation by suppressing the secretion of CCL5 from astrocytes","volume":"10","author":"Sun","year":"2019","journal-title":"Cell Death Dis."},{"key":"10.1016\/j.ymthe.2024.12.016_bib67","doi-asserted-by":"crossref","first-page":"1723","DOI":"10.1056\/NEJMoa1702752","article-title":"Nusinersen versus Sham Control in Infantile-Onset Spinal Muscular Atrophy","volume":"377","author":"Finkel","year":"2017","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.ymthe.2024.12.016_bib68","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1016\/S2352-4642(21)00100-0","article-title":"Treatment of infantile-onset spinal muscular atrophy with nusinersen: final report of a phase 2, open-label, multicentre, dose-escalation study","volume":"5","author":"Finkel","year":"2021","journal-title":"Lancet Child Adolesc. Health"},{"key":"10.1016\/j.ymthe.2024.12.016_bib69","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1038\/s43856-023-00256-2","article-title":"Nusinersen mitigates neuroinflammation in severe spinal muscular atrophy patients","volume":"3","author":"Nuzzo","year":"2023","journal-title":"Commun. Med."},{"key":"10.1016\/j.ymthe.2024.12.016_bib70","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1186\/s13024-018-0297-x","article-title":"Development and validation of a simplified method to generate human microglia from pluripotent stem cells","volume":"13","author":"McQuade","year":"2018","journal-title":"Mol. Neurodegener."},{"key":"10.1016\/j.ymthe.2024.12.016_bib71","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1038\/nbt.3049","article-title":"Combinatorial analysis of developmental cues efficiently converts human pluripotent stem cells into multiple neuronal subtypes","volume":"33","author":"Maury","year":"2015","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.ymthe.2024.12.016_bib72","doi-asserted-by":"crossref","first-page":"1830","DOI":"10.1093\/hmg\/ddab365","article-title":"Assessment of cerebral spinal fluid biomarkers and microRNA-mediated disease mechanisms in spinal muscular atrophy patient samples","volume":"31","author":"Welby","year":"2022","journal-title":"Hum. Mol. Genet."}],"container-title":["Molecular Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1525001624008153?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1525001624008153?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,3,6]],"date-time":"2025-03-06T13:25:36Z","timestamp":1741267536000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1525001624008153"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2]]},"references-count":72,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2025,2]]}},"alternative-id":["S1525001624008153"],"URL":"https:\/\/doi.org\/10.1016\/j.ymthe.2024.12.016","relation":{"has-preprint":[{"id-type":"doi","id":"10.1101\/2023.08.10.552842","asserted-by":"object"}]},"ISSN":["1525-0016"],"issn-type":[{"value":"1525-0016","type":"print"}],"subject":[],"published":{"date-parts":[[2025,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"IL-1ra and CCL5, but not IL-10, are promising targets for treating SMA astrocyte-driven pathology","name":"articletitle","label":"Article Title"},{"value":"Molecular Therapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ymthe.2024.12.016","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Author(s). Published by Elsevier Inc. on behalf of The American Society of Gene and Cell Therapy.","name":"copyright","label":"Copyright"}]}}